1984•PubMedRequires access

[Ceftazidime: antibacterial activity and clinical efficacy in obstetrics and gynecology].

Kiyoshi Ninomiya, T Yoshimoto, Yasuhiro Hasegawa

Open publisher page 0 citations

Abstract

Ceftazidime ( CAZ ) exhibited in vitro activity greater than cefoperazone, cefotiam, cefmetazole and cefazolin and almost equal to cefotaxime (CTX), ceftizoxime (CZX) and latamoxef ( LMOX ) against E. coli and K. pneumoniae isolated from obstetrical or gynecological infections excluding urinary tract infections. This drug demonstrated less activity than other 6 cephems against B. fragilis. Against anaerobic Gram-positive cocci, it showed less activity than other cephems. CAZ was administered to 11 patients with obstetrical and gynecological infections. The clinical results of this drug were as follows; excellent in each 1 case of parametritis , wound infection and BARTHOLIN's abscess, good in 7 cases including 1 of puerperal fever, 2 of intrauterine infection and 4 of adnexitis, and poor in 1 cases of adnexitis. No side effects or haematobiochemical abnormalities were observed throughout this trial.

About this research paper

What this paper is about

Ceftazidime ( CAZ ) exhibited in vitro activity greater than cefoperazone, cefotiam, cefmetazole and cefazolin and almost equal to cefotaxime (CTX), ceftizoxime (CZX) and latamoxef ( LMOX ) against E. coli and K. pneumoniae isolated from obstetrical or gynecological infections excluding urinary tract infections. This drug demonstrated less activity than other 6 cephems against B. fragilis. Against anaerobic Gram-positive cocci, it showed less activity than other cephems. CAZ was administered to 11 patients with obstetrical and gynecological infections. The clinical results of this drug were as follows; excellent in each 1 case of parametritis , wound infection and BARTHOLIN's abscess, good in 7 cases including 1 of puerperal fever, 2 of intrauterine infection and 4 of adnexitis, and poor in 1 cases of adnexitis. No side effects or haematobiochemical abnormalities were observed throughout this trial.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Ceftazidime ( CAZ ) exhibited in vitro activity greater than cefoperazone, cefotiam, cefmetazole and cefazolin and almost equal to cefotaxime (CTX), ceftizoxime (CZX) and latamoxef ( LMOX ) against E. coli and K. pneumoniae isolated from obstetrical or gynecological infections excluding urinary tract infections. This drug demonstrated less activity than other 6 cephems against B. fragilis. Against anaerobic Gram-positive cocci, it showed less activity than other cephems. CAZ was administered to 11 patients with obstetrical and gynecological infections. The clinical results of this drug were as follows; excellent in each 1 case of parametritis , wound infection and BARTHOLIN's abscess, good in 7 cases including 1 of puerperal fever, 2 of intrauterine infection and 4 of adnexitis, and poor in 1 cases of adnexitis. No side effects or haematobiochemical abnormalities were observed throughout this trial.

Key concepts: Ceftizoxime, Cefotiam, Cefmetazole, Latamoxef, Ceftazidime, Cefoperazone, Cefazolin, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[Ceftazidime: antibacterial activity and clinical efficacy in obstetrics and gynecology]. — Research Paper | ScholarLens